Your browser doesn't support javascript.
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi, Hiroya; Nakamura, Yoshiaki; Kotani, Daisuke; Yukami, Hiroki; Mishima, Saori; Sawada, Kentaro; Shirasu, Hiromichi; Ebi, Hiromichi; Yamanaka, Takeharu; Aleshin, Alexey; Billings, Paul R; Rabinowitz, Matthew; Oki, Eiji; Takemasa, Ichiro; Kato, Takeshi; Mori, Masaki; Yoshino, Takayuki.
  • Taniguchi H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Nakamura Y; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Kotani D; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Yukami H; Translational Research Support Section, National Cancer Center Hospital East, Kashiwa, Japan.
  • Mishima S; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Sawada K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Shirasu H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Ebi H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Yamanaka T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Japan.
  • Aleshin A; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Billings PR; Department of Biostatistics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Rabinowitz M; Natera, Inc., San Carlos, CA, USA.
  • Oki E; Natera, Inc., San Carlos, CA, USA.
  • Takemasa I; Natera, Inc., San Carlos, CA, USA.
  • Kato T; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Mori M; Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan.
  • Yoshino T; Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Cancer Sci ; 112(7): 2915-2920, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1294969
Semantic information from SemMedBD (by NLM)
1. Adjuvant Therapy TREATS Colorectal Carcinoma
Subject
Adjuvant Therapy
Predicate
TREATS
Object
Colorectal Carcinoma
2. Colorectal Carcinoma PROCESS_OF Patients
Subject
Colorectal Carcinoma
Predicate
PROCESS_OF
Object
Patients
3. Chemotherap PREVENTS C0521158
Subject
Chemotherap
Predicate
PREVENTS
Object
C0521158
4. Adjuvant Therapy TREATS Resectable Colorectal Carcinoma
Subject
Adjuvant Therapy
Predicate
TREATS
Object
Resectable Colorectal Carcinoma
5. Complete excision TREATS Recurrent Colorectal Carcinoma
Subject
Complete excision
Predicate
TREATS
Object
Recurrent Colorectal Carcinoma
6. Curative Surgery PRECEDES Capecitabine/Oxaliplatin
Subject
Curative Surgery
Predicate
PRECEDES
Object
Capecitabine/Oxaliplatin
7. Capecitabine/Oxaliplatin TREATS Patients
Subject
Capecitabine/Oxaliplatin
Predicate
TREATS
Object
Patients
8. Placebos TREATS Colorectal Carcinoma
Subject
Placebos
Predicate
TREATS
Object
Colorectal Carcinoma
9. tipiracil / trifluridine TREATS Colorectal Carcinoma
Subject
tipiracil / trifluridine
Predicate
TREATS
Object
Colorectal Carcinoma
10. tipiracil / trifluridine compared_with Placebos
Subject
tipiracil / trifluridine
Predicate
compared_with
Object
Placebos
11. Placebos TREATS Patients
Subject
Placebos
Predicate
TREATS
Object
Patients
12. tipiracil / trifluridine TREATS Patients
Subject
tipiracil / trifluridine
Predicate
TREATS
Object
Patients
13. Adjuvant Therapy TREATS Colorectal Carcinoma
Subject
Adjuvant Therapy
Predicate
TREATS
Object
Colorectal Carcinoma
14. Colorectal Carcinoma PROCESS_OF Patients
Subject
Colorectal Carcinoma
Predicate
PROCESS_OF
Object
Patients
15. Chemotherapy, Adjuvant PREVENTS Recurrent tumor
Subject
Chemotherapy, Adjuvant
Predicate
PREVENTS
Object
Recurrent tumor
16. Adjuvant Therapy TREATS Resectable Colorectal Carcinoma
Subject
Adjuvant Therapy
Predicate
TREATS
Object
Resectable Colorectal Carcinoma
17. Complete excision TREATS Recurrent Colorectal Carcinoma
Subject
Complete excision
Predicate
TREATS
Object
Recurrent Colorectal Carcinoma
18. Curative Surgery PRECEDES Capecitabine/Oxaliplatin
Subject
Curative Surgery
Predicate
PRECEDES
Object
Capecitabine/Oxaliplatin
19. Capecitabine/Oxaliplatin TREATS Patients
Subject
Capecitabine/Oxaliplatin
Predicate
TREATS
Object
Patients
20. Placebos TREATS Colorectal Carcinoma
Subject
Placebos
Predicate
TREATS
Object
Colorectal Carcinoma
21. tipiracil / trifluridine TREATS Colorectal Carcinoma
Subject
tipiracil / trifluridine
Predicate
TREATS
Object
Colorectal Carcinoma
22. tipiracil / trifluridine compared_with Placebos
Subject
tipiracil / trifluridine
Predicate
compared_with
Object
Placebos
23. Placebos TREATS Patients
Subject
Placebos
Predicate
TREATS
Object
Patients
24. tipiracil / trifluridine TREATS Patients
Subject
tipiracil / trifluridine
Predicate
TREATS
Object
Patients
ABSTRACT
Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in patients with resected colorectal cancer. Potential utility of circulating tumor DNA (ctDNA) prior to and post surgery has been reported across various solid tumors. We initiated a new type of adaptive platform trials to evaluate the clinical benefits of ctDNA analysis and refine precision adjuvant therapy for resectable colorectal cancer, named CIRCULATE-Japan including three clinical trials. The GALAXY study is a prospectively conducted large-scale registry designed to monitor ctDNA for patients with clinical stage II to IV or recurrent colorectal cancer who can undergo complete surgical resection. The VEGA trial is a randomized phase III study designed to test whether postoperative surgery alone is noninferior to the standard therapy with capecitabine plus oxaliplatin for 3 months in patients with high-risk stage II or low-risk stage III colon cancer if ctDNA status is negative at week 4 after curative surgery in the GALAXY study. The ALTAIR trial is a double-blind, phase III study designed to establish the superiority of trifluridine/tipiracil as compared with placebo in patients with resected colorectal cancer who show circulating tumor-positive status in the GALAXY study. Therefore, CIRCULATE-Japan encompasses both "de-escalation" and "escalation" trials for ctDNA-negative and -positive patients, respectively, and helps to answer whether measuring ctDNA postoperatively has prognostic and/or predictive value. Our ctDNA-guided adaptive platform trials will accelerate clinical development toward further precision oncology in the field of adjuvant therapy. Analysis of ctDNA status could be utilized as a predictor of risk stratification for recurrence and to monitor the effectiveness of adjuvant chemotherapy. ctDNA is a promising, noninvasive tumor biomarker that can aid in tumor monitoring throughout disease management.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Colorectal Neoplasms / Circulating Tumor DNA / Neoplasm Recurrence, Local Type of study: Controlled clinical trial / Observational study / Prognostic study / Randomized controlled trials / Risk factors Limits: Humans Country/Region as subject: Asia Language: English Journal: Cancer Sci Year: 2021 Document Type: Article Affiliation country: Cas.14926

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Colorectal Neoplasms / Circulating Tumor DNA / Neoplasm Recurrence, Local Type of study: Controlled clinical trial / Observational study / Prognostic study / Randomized controlled trials / Risk factors Limits: Humans Country/Region as subject: Asia Language: English Journal: Cancer Sci Year: 2021 Document Type: Article Affiliation country: Cas.14926